

Lists of structure factors, anisotropic displacement parameters, H-atom coordinates and complete geometry have been deposited with the IUCr (Reference: NA1145). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

- Carini, D. J., Duncia, J. V., Aldrich, P. E., Chiu, A. T., Johnson, A. L., Pierce, M. E., Price, W. A., Santella, J. B. III, Wells, G. J., Wexler, R. R., Wong, P. C., Yoo, S.-E. & Timmermans, P. B. M. W. M. (1991). *J. Med. Chem.* **34**, 2525–2547.
- Destro, R., Bianchi, R. & Morosi, G. (1989). *J. Phys. Chem.* **93**, 4447–4457.
- Frenz, B. A. (1983). *Enraf-Nonius Structure Determination Package; SDP User's Guide*. Version of 6 January 1983. Enraf-Nonius, Delft, The Netherlands.
- Johnson, A. L., Carini, D. J., Chiu, A. T., Duncia, J. V., Price, W. A. Jr., Wells, G. J., Wexler, R. R., Wong, P. C. & Timmermans, P. B. M. W. M. (1990). *Drug News Perspect.* **3**, 337–351.
- Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
- Main, P., Fiske, S. J., Hull, S. E., Lessinger, L., Germain, G., Declercq, J.-P. & Woolfson, M. M. (1982). *MULTAN11/82. A System of Computer Programs for the Automatic Solution of Crystal Structures from X-ray Diffraction Data*. Univs. of York, England, and Louvain, Belgium.
- Scolastico, C. & Salimbeni, A. (1994). Personal communication.
- Sheldrick, G. M. (1993). *SHELXL93. Program for the Refinement of Crystal Structures*. Univ. of Göttingen, Germany.
- Valloton, M. B. (1987). *Trends Pharmacol. Sci.* **8**, 69–74.

Acta Cryst. (1995). **C51**, 1385–1388

3-Amino-4*H*-pyrido[4,3-*e*]-1,2,4-thiadiazine 1,1-dioxide Monohydrate and 3-*tert*-Butyl-4*H*-pyrido[4,3-*e*]-1,2,4-thiadiazine 1,1-dioxide

LÉON DUPONT

Unité de Cristallographie, Institut de Physique B5,
Université de Liège au Sart Tilman, B-4000 Liège,
Belgium

BERNARD PIROTTE, PASCAL DE TULLIO,
BERNARD MASEREEL AND JACQUES DELARGE

Laboratoire de Chimie Pharmaceutique, Institut de
Pharmacie F1, Université de Liège, Rue Fusch 5,
B-4000 Liège, Belgium

(Received 9 November 1994; accepted 3 January 1995)


Abstract

The title compounds, $C_6H_6N_4O_2S \cdot H_2O$, (I), and $C_{10}H_{13}N_3O_2S$, (II), were prepared for structural and pharmacological comparison with diazoxide, an antihypertensive


agent. The crystal structure determinations show that the 4*H*- (rather than the 2*H*-) tautomeric form is preferentially adopted by these pyridothiadiazine derivatives in the solid state, as has also been found for diazoxide and other 1,2,4-thiadiazine 1,1-dioxide analogues. The *tert*-butyl moiety in (II) is slightly disordered.

Comment

3-Amino-4*H*-pyrido[4,3-*e*]-1,2,4-thiadiazine 1,1-dioxide monohydrate, (I), is a heterocyclic compound for which the synthesis and the biological evaluation on insulin-secreting cells in comparison with diazoxide [7-chloro-3-methyl-2*H*(or 4*H*)-1,2,4-benzothiadiazine 1,1-dioxide] has recently been reported (Pirotte *et al.*, 1993). In the crystalline state, the thiadiazine and water molecules are linked by the hydrogen bonds N4—H4···O3 [N4···O3 2.676 (3), H4···O3 1.69 (2) Å, N4—H4···O3 165 (1)°], N11—H111···O2ⁱ [N11···O2ⁱ 3.100 (3), H111···O2ⁱ 2.39 (2) Å, N11—H111···O2ⁱ 134 (1)°], N11—H112···O1ⁱⁱ [N11···O1ⁱⁱ 2.959 (3), H112···O1ⁱⁱ 2.13 (2) Å, N11—H112···O1ⁱⁱ 162 (2)°], O3—H31···O2ⁱⁱⁱ [O3···O2ⁱⁱⁱ 2.841 (4), H31···O2ⁱⁱⁱ 1.87 (3) Å, O3—H31···O2ⁱⁱⁱ 172 (1)°] and O3—H32···N8^{iv} [O3···N8^{iv} 2.730 (3), H32···N8^{iv} 1.76 (2) Å, O3—H32···N8^{iv} 180 (1)°] [symmetry codes: (i) $\frac{1}{2} - x, -\frac{1}{2} + y, -z$; (ii) $-x, -y, -z$; (iii) $1 - x, -y, -z$; (iv) $\frac{3}{2} - x, -\frac{1}{2} + y, 1 - z$].



3-*tert*-Butyl-4*H*-pyrido[4,3-*e*]-1,2,4-thiadiazine 1,1-dioxide, (II), was also investigated in order to compare its molecular structure with that of diazoxide. An article describing the preparation and the synthesis of the product, and the biological evaluation, is in preparation (Pirotte *et al.*, 1995). The molecules are linked by the hydrogen bond N4—H4···O1ⁱ [N4···O1ⁱ 2.981 (4), H4···O1ⁱ 2.08 (2) Å, N4—H4···O1ⁱ 156 (1)°; symmetry code: (i) $\frac{1}{2} - x, -\frac{1}{2} + y, 1 - z$].



In both crystal structures the N2—C3 and N4—C3 bond lengths, the location of the H atom on N4 rather than on N2, and the hydrogen-bonding schemes indicate that the 4*H*- form is favoured in the solid state. The same conclusion has been drawn for diazoxide

(Bandoli & Nicolini, 1977) and for some other thiadiazine derivatives, for example 3-methyl-4*H*-pyrido-[4,3-*e*]-1,2,4-thiadiazine 1,1-dioxide monohydrate, (III) (Dupont, de Tullio, Pirotte, Masereel & Delarge, 1995). The presence of the 3-amino group in (I) instead of the 3-*tert*-butyl group in (II) or the 3-methyl group in (III) results in a lengthening of the N2—C3 bond.




Fig. 1. Molecular structure of (I) with the atom-labelling scheme. Displacement ellipsoids are shown at the 50% probability level; H atoms are drawn as small circles of arbitrary radii.




Fig. 2. Molecular structure of (II) with the atom-labelling scheme. Displacement ellipsoids are shown at the 50% probability level; H atoms are drawn as small circles of arbitrary radii.

Experimental

Compounds (I) and (II) were synthesized as described by Pirotte *et al.* (1993, 1995) at the Laboratory of Medicinal Chemistry, Liège. Crystals of (I) were obtained by slow evaporation of a water-methanol solution (75/25% by volume) at room temperature. Crystals of (II) were grown by slow evaporation of a methanol solution at room temperature.

Compound (I)

Crystal data

$C_6H_6N_4O_2S \cdot H_2O$
 $M_r = 216.22$

$Cu K\alpha$ radiation
 $\lambda = 1.5418 \text{ \AA}$

Monoclinic
 $P2_1/a$
 $a = 7.487(2) \text{ \AA}$
 $b = 15.470(7) \text{ \AA}$
 $c = 8.131(7) \text{ \AA}$
 $\beta = 109.55(3)^\circ$
 $V = 887.5(9) \text{ \AA}^3$
 $Z = 4$
 $D_x = 1.618 \text{ Mg m}^{-3}$

Cell parameters from 21 reflections
 $\theta = 18.55\text{--}34.66^\circ$
 $\mu = 3.208 \text{ mm}^{-1}$
 $T = 293(2) \text{ K}$
Prism
 $0.38 \times 0.11 \times 0.08 \text{ mm}$
Colourless

Data collection

Stoe Siemens AED four-circle diffractometer
 ω scans
Absorption correction:
 ψ scan
 $T_{\min} = 0.5820$, $T_{\max} = 0.7014$
1219 measured reflections
1219 independent reflections

964 observed reflections
 $[I > 2\sigma(I)]$
 $\theta_{\max} = 59.19^\circ$
 $h = 0 \rightarrow 8$
 $k = 0 \rightarrow 16$
 $l = -9 \rightarrow 8$
2 standard reflections
frequency: 60 min
intensity decay: 2.6%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.0342$
 $wR(F^2) = 0.1002$
 $S = 1.173$
1219 reflections
130 parameters
H atoms were constrained and included as riding atoms, except for the 4*H*-atom and water H atoms, which were kept fixed
 $w = 1/[\sigma^2(F_o^2) + (0.0686P)^2 + 0.1258P]$
where $P = (F_o^2 + 2F_c^2)/3$

$(\Delta/\sigma)_{\max} < 0.001$
 $\Delta\rho_{\max} = 0.179 \text{ e \AA}^{-3}$
 $\Delta\rho_{\min} = -0.260 \text{ e \AA}^{-3}$
Extinction correction:
SHELXL93 (Sheldrick, 1993)
Extinction coefficient:
0.0104 (11)
Atomic scattering factors from *International Tables for Crystallography* (1992, Vol. C, Tables 4.2.6.8 and 6.1.1.4)

Compound (II)

Crystal data

$C_{10}H_{13}N_3O_2S$
 $M_r = 239.29$
Monoclinic
 $P2_1/a$
 $a = 9.802(9) \text{ \AA}$
 $b = 11.682(9) \text{ \AA}$
 $c = 10.384(16) \text{ \AA}$
 $\beta = 108.00(10)^\circ$
 $V = 1130.9(23) \text{ \AA}^3$
 $Z = 4$
 $D_x = 1.405 \text{ Mg m}^{-3}$

$Cu K\alpha$ radiation
 $\lambda = 1.5418 \text{ \AA}$
Cell parameters from 24 reflections
 $\theta = 24.47\text{--}39.93^\circ$
 $\mu = 2.477 \text{ mm}^{-1}$
 $T = 293(2) \text{ K}$
Prism
 $0.38 \times 0.38 \times 0.15 \text{ mm}$
Colourless

Data collection

Stoe Siemens AED four-circle diffractometer
 ω scans
Absorption correction:
 ψ scan
 $T_{\min} = 0.3774$, $T_{\max} = 0.6191$
1566 measured reflections
1566 independent reflections

1388 observed reflections
 $[I > 2\sigma(I)]$
 $\theta_{\max} = 59.08^\circ$
 $h = 0 \rightarrow 10$
 $k = 0 \rightarrow 12$
 $l = -11 \rightarrow 10$
2 standard reflections
frequency: 60 min
intensity decay: 3.5%

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.0443$
 $wR(F^2) = 0.1276$
 $S = 1.160$
1566 reflections
151 parameters
H atoms were constrained
and included as riding
atoms, except for the 4H-
atom, which was kept
fixed
 $w = 1/[\sigma^2(F_o^2) + (0.0785P)^2$
+ 0.6684P]
where $P = (F_o^2 + 2F_c^2)/3$

$(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.348 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.379 \text{ e \AA}^{-3}$
Extinction correction:
SHELXL93 (Sheldrick,
1993)
Extinction coefficient:
0.0151 (13)
Atomic scattering factors
from International Tables
for Crystallography (1992,
Vol. C, Tables 4.2.6.8 and
6.1.1.4)

C9—C10	1.383 (4)	1.385 (4)	
C11—C13	1.511 (5)		
C11—C12	1.513 (5)		
C11—C14	1.514 (5)		
O2—S1—O1	114.80 (12)	115.84 (13)	
O2—S1—N2	108.92 (13)	108.6 (2)	
O1—S1—N2	110.46 (12)	108.25 (13)	
O2—S1—C10	109.24 (12)	108.99 (14)	
O1—S1—C10	108.03 (13)	109.79 (14)	
N2—S1—C10	104.92 (12)	104.8 (2)	
C3—N2—S1	122.0 (2)	123.3 (2)	
N2—C3—N11	119.4 (2)	119.0 (2)	
N2—C3—N4	124.6 (2)	124.7 (2)	
N11—C3—N4	115.9 (2)	116.3 (2)	
C3—N4—C5	123.3 (2)	123.9 (2)	
N4—C5—C6	120.6 (2)	120.9 (3)	
N4—C5—C10	121.5 (2)	120.8 (2)	
C6—C5—C10	117.9 (2)	118.3 (3)	
C7—C6—C5	119.0 (3)	117.8 (3)	
N8—C7—C6	123.7 (3)	125.3 (3)	
C9—N8—C7	117.1 (2)	116.0 (3)	
N8—C9—C10	123.3 (3)	124.2 (3)	
C9—C10—C5	119.0 (3)	118.3 (3)	
C9—C10—S1	122.4 (2)	122.4 (2)	
C5—C10—S1	118.5 (2)	119.2 (2)	
C13—C11—C12	111.7 (4)		
C13—C11—C14	108.0 (3)		
C12—C11—C14	109.1 (3)		
C13—C11—C3	110.3 (3)		
C12—C11—C3	108.8 (3)		
C14—C11—C3	108.9 (2)		
O2—S1—N2—C3	142.1 (2)	98.4 (3)	
O1—S1—N2—C3	-90.9 (2)	-135.1 (2)	
C10—S1—N2—C3	25.3 (2)	-18.0 (3)	
S1—N2—C3—N11	166.3 (2)	S1—N2—C3—C11	-173.9 (2)
S1—N2—C3—N4	-17.2 (4)		7.5 (4)
N2—C3—N4—C5	-3.5 (4)		7.4 (4)
N11—C3—N4—C5	173.1 (2)	C11—C3—N4—C5	-171.2 (2)
C3—N4—C5—C10	10.1 (4)		-6.4 (4)
N4—C5—C10—S1	2.9 (3)		-7.7 (3)
O2—S1—C10—C5	-134.9 (2)		-98.3 (2)
O1—S1—C10—C5	99.5 (2)		133.9 (2)
N2—S1—C10—C5	-18.3 (2)		17.8 (2)

The values of the anisotropic displacement parameters of C12, C13 and C14 [compound (II), see Fig. 2] show that the tert-butyl group is slightly disordered.

For both compounds, data collection: DIF4 (Stoe & Cie, 1988a); cell refinement: DIF4; data reduction: REDU4 (Stoe & Cie, 1988b); program(s) used to solve structures: SHELXS86 (Sheldrick, 1985); program(s) used to refine structures: SHELXL93 (Sheldrick, 1993); molecular graphics: ORTEPII (Johnson, 1976); software used to prepare material for publication: SHELXL93.

The authors thank M. M. Vermeire for his helpful assistance in the diffractometry measurements and the FNRS for financial support.

Table 2. Selected geometric parameters (\AA , $^\circ$)

	(I)	(II)	
S1—O2	1.437 (2)	1.428 (2)	
S1—O1	1.440 (2)	1.434 (2)	
S1—N2	1.582 (2)	1.595 (3)	
S1—C10	1.742 (3)	1.731 (3)	
N2—C3	1.321 (3)	1.295 (4)	
C3—N11	1.328 (3)	C3—C11	1.515 (4)
C3—N4	1.355 (3)		1.356 (4)
N4—C5	1.378 (3)		1.375 (4)
C5—C6	1.387 (4)		1.393 (4)
C5—C10	1.390 (3)		1.381 (4)
C6—C7	1.366 (4)		1.359 (5)
C7—N8	1.349 (4)		1.335 (4)
N8—C9	1.327 (4)		1.316 (4)


Lists of structure factors, anisotropic displacement parameters, H-atom coordinates and complete geometry have been deposited with the IUCr (Reference: AB1238). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

- Bandoli, G. & Nicolini, M. (1977). *J. Cryst. Mol. Struct.* **7**, 229–240.
Dupont, L., de Tullio, P., Pirotte, B., Masereel, B. & Delarge, J. (1995). *Acta Cryst. C51*, 946–948.

- Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
- Pirotte, B., de Tullio, P., Lebrun, P., Antoine, M.-H., Fontaine, J., Masereel, B., Schynts, M., Dupont, L., Herchuelz, A. & Delarge, J. (1993). *J. Med. Chem.* **36**, 3211–3213.
- Pirotte, B., de Tullio, P., Lebrun, P., Antoine, M.-H., Fontaine, J., Masereel, B., Schynts, M., Dupont, L., Herchuelz, A. & Delarge, J. (1995). In preparation.
- Sheldrick, G. M. (1985). *SHELXS86. Program for the Solution of Crystal Structures*. Univ. of Göttingen, Germany.
- Sheldrick, G. M. (1993). *SHELXL93. Program for the Refinement of Crystal Structures*. Univ. of Göttingen, Germany.
- Stoe & Cie (1988a) *DIF4. Diffractometer Control Program*. Version 6.2D. Stoe & Cie, Darmstadt, Germany.
- Stoe & Cie (1988b) *REDU4. Data Reduction Program*. Version 6.2D. Stoe & Cie, Darmstadt, Germany.

des Urotropins offensichtlich nicht mehr gewachsen. Die bisher fehlende Kristallstruktur des Molekülkomplexes haben wir zur Vervollständigung der Reihe ermittelt.



Die Lageparameter sind in Tabelle 1 und die wichtigeren geometrischen Größen in Tabelle 2 aufgelistet. Die Bezeichnung der Atome geht aus Fig. 1 hervor.




Fig. 1. Struktur der Baugruppen mit thermischen Ellipsoiden (50% Wahrscheinlichkeit) und den Atombezeichnungen. Auf eine Darstellung der H-Atome wurde zugunsten der Übersichtlichkeit verzichtet.

Strukturell lassen sich sämtliche Iodaddukte des Urotropins durch eine lineare Anordnung von Donoratom und Halogenmolekül charakterisieren, wobei das Halogenmolekül in Richtung des freien Elektronenpaares des Donoratoms ausgerichtet ist. Wie erwartet wird jeweils nach Knüpfung des kurzen Donor-Halogen-Abstands eine Streckung des Halogenmoleküls beobachtet.

In dem hier vorgestellten Molekülkomplex Ur.3I₂ der Symmetrie 3 liegt diesen Merkmalen entsprechend eine annähernd lineare Baueinheit N···I—I mit einseitig koordiniertem Iodmolekül vor. Die Bindungswinkel C—N···I an den Donor-N-Atomen bleiben wie bei den beiden Vergleichsstrukturen Ur.I₂ und Ur.2I₂ in der

Acta Cryst. (1995). **C51**, 1388–1390

Urotropin-3-Diiod, Ur.3I₂

KARL-FRIEDRICH TEBBE UND KLAUS NAGEL

*Institut für Anorganische Chemie, Universität zu Köln,
Greinstraße 6, D-50939 Köln, Deutschland*

(Eingegangen am 3. November 1994; angenommen am 22. Dezember 1994)

Abstract

The structure of 1,3,5,7-tetraazatricyclo[3.3.1.1^{3,7}]decane tris(diiodine), $C_6H_{12}N_4 \cdot 3I_2$, has been determined. The high-symmetry compound belongs to the class of $n-\sigma^*$ donor–acceptor complexes and shows the structural features of this group of compounds.

Kommentar

Bisher sind drei Molekülkomplexe Ur. nI_2 des Urotropins $C_6H_{12}N_4$ mit Iod I_2 für $n = 1, 2, 3$ beschrieben worden (Bowmaker & Knappstein, 1977), von denen die beiden iodärmeren Ur.I₂ und Ur.2I₂ auch strukturell als Donor-Akzeptor-Komplexe vom Typ $n-\sigma^*$ charakterisiert werden konnten (Pritzkow, 1975b) und der iodärmste zusätzlich in ionischer Form $(Ur_2I)I_3$ als Triiodid des Bis(urotropin)iodonium-Kations auftreten kann (Bowmaker & Hannan, 1971; Pritzkow, 1975a). Durch Umsetzung von Urotropiniumiodid UrHI mit Iod I_2 lässt sich dagegen ein salzartiges Urotropiniumtriiodid UrHI₃ gewinnen (Tebbe & Nagel, 1995). Bei Versuchen zur Darstellung iodreicherer Polyiodide des Urotropiniumions UrHI_n mit $n > 3$ durch Erhöhung des Iodangebots erhalten wir allerdings überraschend den bisher iodreichsten Molekülkomplex Ur.3I₂. Einer dreifachen Koordination durch Iod ist die Protonierung